{"filing":{"accession_number":"0001104659-26-104145","cik":"0001847367","ticker":"ALMS","company_name":"ALUMIS INC.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"tm2624540d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_8k.htm"},"events":[{"id":30811,"run_id":28252,"accession_number":"0001104659-26-104145","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Alumis announced topline results from its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE). The trial did not meet its primary and secondary endpoints in the overall population, but showed robust responses in a prespecified IFNGS-high subgroup, supporting Phase 3 development. This is a material clinical development milestone for a late-stage biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, though it does not fit neatly into earnings, M\u0026A, impairment, or other specific event categories.","company_name":"ALUMIS INC.","ticker":"ALMS","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33528,"accession_number":"0001104659-26-104145","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alumis announced topline results from its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE). The trial did not meet its primary and secondary endpoints in the overall population, but showed robust responses in a prespecified IFNGS-high subgroup, supporting Phase 3 development. This is a material clinical development milestone for a late-stage biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, though it does not fit neatly into earnings, M\u0026A, impairment, or other specific event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T12:32:10.534105+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33528,"accession_number":"0001104659-26-104145","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Alumis announced topline results from its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE). The trial did not meet its primary and secondary endpoints in the overall population, but showed robust responses in a prespecified IFNGS-high subgroup, supporting Phase 3 development. This is a material clinical development milestone for a late-stage biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, though it does not fit neatly into earnings, M\u0026A, impairment, or other specific event categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T12:32:10.534105+00:00","company_name":"ALUMIS INC.","ticker":"ALMS","filing_date":"2026-09-01"}]}